EMAS registration for Kedrion: the company’s environmental policy reinforced
Kedrion SpA, specialized in the production of plasma–derived products, is one of the five Italian pharmaceutical companies which got EMAS registration. The company has joined an “Environmental Programme” and has thereby assumed specific environmental policy commitments. At the same time, it has drawn up an “Environmental Statement” which – in terms of regulation CE 761/2001
New plant in the Kedrion factory: 7 million invested and a 50% increase in production of Factor VIII and Factor IX
The new production department for sterile “Filling and Freeze-Drying of Heat-treated Coagulation Factors” in the Kedrion factory in Bolognana is now in operation. 7 million euros invested and a forecast increase of 50% in the production of Factor VIII and Factor IX which currently represent the 20% of turnover and the asset for the Contract
Plasma system, exporting the Italian “Contract Manufacturing” model to Chile
“Teamwork to improve plasma quality in Chile” is based on an agreement made in November 2005 by the Ministry of Health in Chile and SIMTI (Italian Transfusion Medicine and Immunohaematology Company), which marked the operational meeting between the Chilean delegation specially flown in to Italy and the CNR (National Research Council), SIMTI, Tuscany’s CRCC (Regional
Plasma derivates: reinforcing Tuscany as leader in the Balkans
Kedrion Biopharmaceuticals has won a contract to supply FIX in Bosnia. This is the plasma-derived drug used in the treatment of Haemophilia B (incidence of 1 in 60,000 people) which has a world market worth 200 million US dollars, with production of 430 million international units and distribution of 42% in Europe, 24% in North
Plasmaderivatives: “Investitori Associati” invests in the sector with a 40% share in leading company Kedrion
Investitori Associati SGR, the common fund management company for closed-end security investment, is investing in the plasmaderivatives sector with a 40% share in Kedrion SpA, the leading company in Italy in this area. It belongs to the Marcucci family who will retain the majority holding with 60% of the shares. The operation, financed by Banca
First Russian factory plasma-derived products of internal standard to be set up with Kedrion technology
Kedrion, the leading biopharmaceutical company in the haemoderivatives sector whose principal headquarters is in Tuscany, is to set up a technology exchange in Russia. In 2006, in Kirov in the Volga region, work will begin to set up the first Russian factory producing international standard plasma-derived products. The factory, which will be fully operating by
